NCT02755948 - Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

February 1, 2020

Study Completion Date

February 1, 2020

Conditions

Respiratory Syncytial Virus InfectionsInfluenza, Human

Interventions

BIOLOGICAL

RSV A Memphis 37

Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops

BIOLOGICAL

Influenza A/California/04/2009-likw (H1N1)

Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops

BIOLOGICAL

Influenza A/Belgium/4217/2015 (H3N2)

Good Manufacturing Practices-certified Influenza A/Belgium/4217/2015 (H3N2) 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops

Trial Locations (1)

National Heart and Lung Institute, Imperial College London, London